Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Corrigendum Free access | 10.1172/jci.insight.127684

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Alfred L. Garfall, Edward A. Stadtmauer, Wei-Ting Hwang, Simon F. Lacey, Jan Joseph Melenhorst, Maria Krevvata, Martin P. Carroll, William H. Matsui, Qiuju Wang, Madhav V. Dhodapkar, Kavita Dhodapkar, Rituparna Das, Dan T. Vogl, Brendan M. Weiss, Adam D. Cohen, Patricia A. Mangan, Emily C. Ayers, Selene Nunez-Cruz, Irina Kulikovskaya, Megan M. Davis, Anne Lamontagne, Karen Dengel, Naseem D.S. Kerr, Regina M. Young, Donald L. Siegel, Bruce L. Levine, Michael C. Milone, Marcela V. Maus, and Carl H. June

Find articles by Garfall, A. in: JCI | PubMed | Google Scholar

Find articles by Stadtmauer, E. in: JCI | PubMed | Google Scholar

Find articles by Hwang, W. in: JCI | PubMed | Google Scholar

Find articles by Lacey, S. in: JCI | PubMed | Google Scholar

Find articles by Melenhorst, J. in: JCI | PubMed | Google Scholar

Find articles by Krevvata, M. in: JCI | PubMed | Google Scholar

Find articles by Carroll, M. in: JCI | PubMed | Google Scholar

Find articles by Matsui, W. in: JCI | PubMed | Google Scholar

Find articles by Wang, Q. in: JCI | PubMed | Google Scholar

Find articles by Dhodapkar, M. in: JCI | PubMed | Google Scholar

Find articles by Dhodapkar, K. in: JCI | PubMed | Google Scholar

Find articles by Das, R. in: JCI | PubMed | Google Scholar

Find articles by Vogl, D. in: JCI | PubMed | Google Scholar

Find articles by Weiss, B. in: JCI | PubMed | Google Scholar

Find articles by Cohen, A. in: JCI | PubMed | Google Scholar

Find articles by Mangan, P. in: JCI | PubMed | Google Scholar

Find articles by Ayers, E. in: JCI | PubMed | Google Scholar

Find articles by Nunez-Cruz, S. in: JCI | PubMed | Google Scholar

Find articles by Kulikovskaya, I. in: JCI | PubMed | Google Scholar

Find articles by Davis, M. in: JCI | PubMed | Google Scholar

Find articles by Lamontagne, A. in: JCI | PubMed | Google Scholar

Find articles by Dengel, K. in: JCI | PubMed | Google Scholar

Find articles by Kerr, N. in: JCI | PubMed | Google Scholar

Find articles by Young, R. in: JCI | PubMed | Google Scholar

Find articles by Siegel, D. in: JCI | PubMed | Google Scholar

Find articles by Levine, B. in: JCI | PubMed | Google Scholar

Find articles by Milone, M. in: JCI | PubMed | Google Scholar

Find articles by Maus, M. in: JCI | PubMed | Google Scholar

Find articles by June, C. in: JCI | PubMed | Google Scholar

Published February 21, 2019 - More info

Published in Volume 4, Issue 4 on February 21, 2019
JCI Insight. 2019;4(4):e127684. https://doi.org/10.1172/jci.insight.127684.
Copyright © 2019, American Society for Clinical Investigation
Published February 21, 2019 - Version history
View PDF

Related article:

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L. Garfall, … , Marcela V. Maus, Carl H. June
Alfred L. Garfall, … , Marcela V. Maus, Carl H. June
Anti-CD19 CAR T cells are safe after autologous stem cell transplantation for multiple myeloma and may prolong response and induce anti-myeloma immunity.
Clinical Medicine Hematology Oncology

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

  • Text
  • PDF
Abstract

BACKGROUND. Multiple myeloma is usually fatal due to serial relapses that become progressively refractory to therapy. CD19 is typically absent on the dominant multiple myeloma cell population but may be present on minor subsets with unique myeloma-propagating properties. To target myeloma-propagating cells, we clinically evaluated autologous T cells transduced with a chimeric antigen receptor (CAR) against CD19 (CTL019). METHODS. Subjects received CTL019 following salvage high-dose melphalan and autologous stem cell transplantation (ASCT). All subjects had relapsed/refractory multiple myeloma and had previously undergone ASCT with less than 1 year progression-free survival (PFS). RESULTS. ASCT + CTL019 was safe and feasible, with most toxicity attributable to ASCT and no severe cytokine release syndrome. Two of 10 subjects exhibited significantly longer PFS after ASCT + CTL019 compared with prior ASCT (479 vs. 181 days; 249 vs. 127 days). Correlates of favorable clinical outcome included peak CTL019 frequency in bone marrow and emergence of humoral and cellular immune responses against the stem-cell antigen Sox2. Ex vivo treatment of primary myeloma samples with a combination of CTL019 and CAR T cells against the plasma cell antigen BCMA reliably inhibited myeloma colony formation in vitro, whereas treatment with either CAR alone inhibited colony formation inconsistently. CONCLUSION. CTL019 may improve duration of response to standard multiple myeloma therapies by targeting and precipitating secondary immune responses against myeloma-propagating cells. TRIAL REGISTRATION. Clinicaltrials.gov identifier NCT02135406. FUNDING. Novartis, NIH, Conquer Cancer Foundation.

Authors

Alfred L. Garfall, Edward A. Stadtmauer, Wei-Ting Hwang, Simon F. Lacey, Jan Joseph Melenhorst, Maria Krevvata, Martin P. Carroll, William H. Matsui, Qiuju Wang, Madhav V. Dhodapkar, Kavita Dhodapkar, Rituparna Das, Dan T. Vogl, Brendan M. Weiss, Adam D. Cohen, Patricia A. Mangan, Emily C. Ayers, Selene Nunez-Cruz, Irina Kulikovskaya, Megan M. Davis, Anne Lamontagne, Karen Dengel, Naseem D.S. Kerr, Regina M. Young, Donald L. Siegel, Bruce L. Levine, Michael C. Milone, Marcela V. Maus, Carl H. June

×

Original citation: JCI Insight. 2018;3(8):e120505. https://doi.org/10.1172/jci.insight.120505

Citation for this corrigendum: JCI Insight. 2019;4(4):e127684. https://doi.org/10.1172/jci.insight.127684

In Table 1, the responses given for patients 1 and 6 are incorrect. The correct responses as well as the definition for SCR are below.

Patient 1, SCR

Patient 6, PD

SCR, stringent complete response.

The article has been updated to reflect these changes.

The authors regret the errors.

Footnotes

See the related article at Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Version history
  • Version 1 (February 21, 2019): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts